Ligand gains foothold in China with liver disease deal
This article was originally published in Scrip
Executive Summary
Ligand Pharmaceuticals has taken an indirect step into China through the granting of licences for this burgeoning market to two clinical-stage programmes and technology acquired as part of its purchase of Metabasis a year ago.